Alkermes has received orphan drug designations in the U.S. and EU for alixorexton, its investigational orexin 2 receptor agonist, advancing late‑stage development in narcolepsy and idiopathic hypersomnia.
Written By: Kalyani Boharapi,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Alkermes has received orphan drug designations in the U.S. and EU for alixorexton, its investigational orexin 2 receptor (OX2R) agonist, advancing development in narcolepsy and idiopathic hypersomnia.
The FDA granted orphan status for idiopathic hypersomnia, while the European Commission recognized alixorexton for narcolepsy. The therapy is in Phase 3 trials for narcolepsy type 1 (NT1) and type 2 (NT2) and Phase 2 evaluation for idiopathic hypersomnia.
Alixorexton previously earned FDA Breakthrough Therapy designation for NT1.
Targeting the Orexin Pathway
Alixorexton is a novel, oral, selective OX2R agonist designed to activate the orexin signaling pathway, a key regulator of wakefulness. Orexin‑producing neurons in the hypothalamus stimulate multiple wake‑promoting networks, and loss of this signaling is a hallmark of narcolepsy type 1. By directly stimulating OX2 receptors, alixorexton may reduce excessive daytime sleepiness across narcolepsy and other hypersomnolence disorders.
Narcolepsy is a rare neurological condition marked by excessive sleepiness, disrupted nighttime sleep, paralysis, and hallucinations; NT1 is additionally defined by cataplexy, a sudden loss of muscle control. Idiopathic hypersomnia is another rare disorder characterized by persistent sleepiness, severe sleep inertia, fatigue, and cognitive impairment despite adequate sleep duration.
Late-Stage Development Continues
The orphan drug designations follow positive results from the Phase 2 Vibrance-1 (NCT06358950) and Vibrance-2 (NCT06555783) studies in patients with NT1 and NT2, which supported advancement into the ongoing phase 3 Brilliance clinical program.
Current studies include Brilliance NT1 (Study 302; NCT07455383), Brilliance NT2 (Study 303; NCT07502443) and Brilliance NT1 (Study 304; NCT07540897)
Alkermes is also conducting the Vibrance-3 phase 2 trial (NCT06843590) in adults with idiopathic hypersomnia, with study completion expected later this year.
While detailed efficacy and safety data from the ongoing pivotal studies have not yet been reported, earlier phase 2 findings demonstrated clinically meaningful improvements in narcolepsy symptoms and supported further development of the candidate.
Regulatory Incentives Strengthen Development Pathway
Orphan drug designation provides important incentives for therapies targeting rare diseases. In the United States, benefits include tax credits for qualified clinical research, exemptions from certain FDA fees, and seven years of market exclusivity following approval. In the European Union, orphan designation can provide regulatory assistance, reduced fees, and up to 10 years of market exclusivity.
Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes, noted that the designations highlight the continuing unmet medical need in narcolepsy and idiopathic hypersomnia and reinforce the potential role of alixorexton as a differentiated treatment option.
Path Toward Pivotal Data
Alkermes now enters a pivotal period for the program as enrollment continues across the phase 3 Brilliance studies and the Vibrance-3 trial progresses toward completion. Upcoming clinical data will be closely watched by clinicians, investors, and sleep medicine specialists as the company seeks to establish alixorexton’s efficacy and safety profile across multiple hypersomnolence disorders.
If successful, alixorexton could emerge as one of the leading next-generation orexin-targeted therapies for patients living with narcolepsy and idiopathic hypersomnia.
Reference
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe | Alkermes plc
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.